Diopter Technologies has announced the completion of early clinical studies for its innovative dissolving amniotic membrane and biopolymer contact lens, a groundbreaking therapeutic device aimed at treating various ocular surface diseases. This device represents a significant advancement in the treatment of conditions such as dry eye syndrome, corneal trauma injuries, and post-surgical wounds, by delivering growth factors directly to the affected area while dissolving over 48-72 hours, thereby eliminating the need for clinical removal.
The lens's key features include sustained growth factor release, a self-dissolving design, and enhanced bioavailability, which collectively work to reduce scarring and inflammation while promoting epithelial regeneration. Initial clinical studies have shown promising results, with no adverse events reported and increased patient comfort compared to standard silicon hydrogel lenses over a 48-hour wear period.
Chris Adams, CEO of Diopter Technologies, highlighted the device's ability to actively deliver healing factors to the eye, transforming ocular surface rehabilitation from passive coverage to intelligent tissue remodeling. The lens is currently undergoing further clinical studies for additional indications, including chemical/thermal injury recovery, post-refractive surgery care, and chronic dry eye management, with plans to launch the product in Q1 2026 following FDA approval.
This development is particularly important as it addresses a significant unmet need in the treatment of ocular surface diseases, offering a non-invasive, effective solution that could improve patient outcomes and quality of life. The technology also expands Diopter Technologies' portfolio in ocular drug delivery, showcasing the company's commitment to merging advanced materials science with clinical ophthalmology to develop innovative treatments.
